XXXiaoping Xing

Xiaoping Xing

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaoping Xing has a total of 390 co-authors. Here are the top co-authors by number of shared publications:

  • Ou Wang

    Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100730

    71 shared publications
  • Mei Li

    Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Translational Medicine Center, State Key Laboratory of Complex Severe and Rare Diseases, National Health Commission Key Laboratory of Endocrinology, Beijing 100730, China

    54 shared publications
  • Yan Jiang

    Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Translational Medicine Center, State Key Laboratory of Complex Severe and Rare Diseases, National Health Commission Key Laboratory of Endocrinology, Beijing 100730, China

    53 shared publications
  • Wei-Bo Xia

    Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Beijing 100730, P.R. China

    44 shared publications
  • Xun-Wu Meng

    Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Beijing 100730, P.R. China

    40 shared publications
  • Weibo Xia

    Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100730

    30 shared publications

Latest Publications

  • Open Access

    Age at Menarche and Osteoporosis: The China Osteoporosis Prevalence Study

    by Yongxuan Wang, Zhixiang Wang, Qichao Sun, Yan Jiang, Yue Chi, Ruizhi Jiajue, Wei Liu, Xiang Li, Qianqian Pang, Ou Wang, et al.

    Menarche marks the onset of high estrogen exposure, yet the relationship between age at menarche (AAM) and osteoporosis is not fully understood. This study aimed to investigate the associations of AAM with bone mineral density (BMD), osteoporosis, and fractures across different age decades. In this cross-sectional study using data from the China Osteoporosis Prevalence Study (COPS), we examined the correlations between AAM and BMD at the femoral neck (FN), total hip (TH), and lumbar spine (LS) in women aged 20-29 to ≥70 years. Peak bone mass was determined based on BMD trends across age groups. Among postmenopausal women, we also assessed the associations of AAM with osteoporosis, vertebral fractures, and clinical fractures within the past five years. This cross-sectional analysis is exploratory and intended to generate hypotheses about the life-course association between AAM and bone health. Later AAM was associated with a a cross-sectional pattern of peak bone mass estimates occurring in older age groups at the FN and TH; however, no significant difference in peak bone mass magnitude was observed between AAM groups. In postmenopausal women, later AAM correlated with lower BMD at the LS and TH, and higher odds of osteoporosis. No significant association with fractures was observed. Later AAM was associated with estimates of peak bone mass timing at older age groups at the FN and TH without altering its magnitude. In postmenopausal women, later AAM was associated with modestly lower LS and TH BMD and higher odds of osteoporosis. Therefore, earlier osteoporosis screening is warranted for these women after menopause, and BMD assessment should include sites beyond the femoral neck.

  • Trabecular bone score in glucocorticoid-induced osteoporosis: A systematic review and meta-analysis

    by Liyuan Kou, Yue Jiang, Min Nie, Yan Jiang, Mei Li, Weibo Xia, Ou Wang, An Song, Xiaoping Xing

  • Open Access

    Pattern of height and weight development in a large cohort of underage Chinese pseudohypoparathyroidism patients from a single center

    by Yi Yang, An Song, Hanze Du, Yan Jiang, Mei Li, Weibo Xia, Xiaoping Xing, Ou Wang, Hui Pan

    Objective: Pseudohypoparathyroidism (PHP) is a rare disorder characterized by hypocalcemia and elevated PTH. Although short stature is a key feature, especially in PHP type 1 (PHP1), growth data in Chinese patients remained limited. Methods: Clinical data, including height, age, and biochemical indices, were retrospectively collected from PHP1 patients at Peking Union Medical College Hospital. Molecular diagnosis was performed using MS-MLPA, Sanger sequencing, and WES. Growth charts for height, weight, and BMI in underage patients were constructed. Results: A total of 92 PHP1 patients (58 males, 34 females), including 32 pseudohypoparathyroidism type 1A (PHP-1A), 49 sporadic pseudohypoparathyroidism type 1B (PHP-S1B), and 11 autosomal dominant pseudohypoparathyroidism type 1B (PHP-AD1B), were recruited. Growth velocity peaked at 12 years in males and 5 years in females, with height plateau at 14 and 13 years, respectively. Adult height was 160.0 cm (SDS −1.04) in males and 155.0 cm (SDS −0.52) in females. PHP-1A patients had significantly shorter adult height than PHP-1B (male: 157.0 ± 6.9 vs 171.9 ± 8.9, P = 0.004; female: 146.8 ± 10.2 vs 156.2 ± 4.9, P = 0.007). PHP-1A showed early-onset weight gain from age 1, persisting into adulthood. Adult Wt-SDS was 1.67 vs 1.55 in males and 2.00 vs 3.10 in females (PHP-1A vs PHP-1B). Weight curves exceeded population P50 in most groups, with no significant differences in adult weight, Wt-SDS, BMI, or obesity prevalence between subtypes. Conclusion: Chinese PHP1 patients show early growth plateau and short stature, more severe in PHP-1A. Obesity varies by subtype and sex, with earlier and more persistent weight gain in PHP-1A. These growth charts may aid clinical management.

  • Risk factors of renal complications in childhood-onset non-surgical hypoparathyroidism: a long-term follow-up study

    by Yingying Chen, Yiyang Gao, Jiajia Wang, An Song, Yan Jiang, Mei Li, Weibo Xia, Xiaoping Xing, Ou Wang

  • Clinical and Genetic Profile of Chinese Familial Hypocalciuric Hypercalcemia Type 1 (FHH1): A Retrospective Study

    by Liyuan Kou, An Song, Min Nie, Yue Jiang, Yingyu Chen, Yiyang Gao, Yan Jiang, Mei Li, Weibo Xia, Ou Wang, et al.

  • Clinical characteristics of chinese patients with autosomal dominant hypocalcemia type 1: a single-center study

    by Yiyang Gao, Yue Jiang, Yabing Wang, Jing Yang, Jiajia Wang, An Song, Yan Jiang, Mei Li, Weibo Xia, Xiaoping Xing, et al.

  • The association of GNAS defects with pro-inflammatory adipokine levels in pseudohypoparathyroidism type 1

    by Yingchun Dong, Yi Yang, An Song, Yan Jiang, Mei Li, Weibo Xia, Fengying Gong, Ou Wang, Xiaoping Xing

  • High prevalence of hyperuricemia and its risk factors in a Chinese cohort of primary hyperparathyroidism patients

    by Runxue Yuan, An Song, Yun Zhang, Yue Sha, Ou Wang, Yan Jiang, Mei Li, Weibo Xia, Xuejun Zeng, Xiaoping Xing

    Purpose Primary hyperparathyroidism (PHPT) is characterized by autonomous and excessive parathyroid hormone (PTH) secretion due to parathyroid gland lesions. Patients can be complicated with hyperuricemia (HUA), however, data about HUA in Chinese PHPT patients are lacking. This study aimed to explore the prevalence of HUA, factors influencing serum uric acid (SUA) level and the impacts of parathyroidectomy (PTX). Methods 328 inpatients diagnosed with PHPT were included in total. Clinical data were collected and compared between HUA and non-HUA group. Multivariate linear regression was used to explore the factors affecting preoperative SUA and its variation after PTX. The impacts of SUA on bone mineral density (BMD) under different models were also analyzed. Results The prevalence of HUA in PHPT patients was nearly 32%. Compared with non-HUA group, HUA group had significantly higher serum calcium (Ca) (2.92 [2.75, 3.26] vs. 2.78 [2.62, 3.03] mmol/L, P < 0.001), while PTH increased without significance. Gender, body mass index, serum Ca, triglycerides and renal function were independently associated with SUA. SUA decreased after PTX (340.00 [291.50, 421.00] vs. 315.00 [270.50, 375.00] μmol/L, P = 0.018), with change of SUA significantly associating with changes in serum Ca and phosphate. Presurgical SUA was positively related with femoral neck, total hip and lumbar spine BMDs after adjusting for confounders. Conclusion A relatively high proportion of HUA was found in our study. Besides the common risk factors, hypercalcemia may contribute to the increased SUA in PHPT patients, which could be significantly improved by curative PTX. SUA might have a protective effect on bone loss in PHPT patients.


  • Open Access

    Two novel rare variants in the PTH gene found in patients with hypoparathyroidism

    by Yue Jiang, An Song, Jiajia Wang, Xinqi Cheng, Jing Yang, Yan Jiang, Mei Li, Weibo Xia, Xiaoping Xing, Min Nie, et al.


  • The Efficacy and Safety of Denosumab for Treating Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Study

    by An Song, Yingyu Chen, Rong Chen, Shuzhong Liu, Liyuan Kou, Jiajia Wang, Min Nie, Yan Jiang, Mei Li, Weibo Xia, et al.

    Context: Denosumab is approved for treating hypercalcemia of malignancy, but data on its efficacy for hypercalcemia related to primary hyperparathyroidism (PHPT) are limited. Objective: To compare the efficacy and safety of denosumab with zoledronic acid in PHPT-related hypercalcemia. Methods: We retrospectively collected data from 29 PHPT patients with moderate/severe hypercalcemia (corrected serum calcium [CSC] ≥ 3.0 mmol/L) treated with denosumab (60 or 120 mg; Dmab group) and CSC-matched 29 PHPT patients treated with zoledronic acid (4 mg; ZA group). The primary efficacy outcome was the change of CSC (ΔCa), while secondary outcomes included the response proportion, time to response, and duration of response. Safety data were also collected. Results: Both groups showed significant reductions in CSC levels (Dmab: 3.37 ± 0.37 mmol/L to 2.64 ± 0.33 mmol/L, P < .01; ZA: 3.41 ± 0.32 mmol/L to 2.57 ± 0.23 mmol/L, P < .01), with similar ΔCa. In the Dmab group, 82.8% (24/29) responded with CSC levels below 3.0 mmol/L, and 72.4% (21/29) achieved complete response (CR, serum CSC less than 2.7 mmol/L), comparable to the ZA group. The time to CR was shorter for ZA (3.0 vs 7.0 days, P < .01), while Dmab had a longer duration of response (19.0 vs 13.0 days, P = .02). Hypocalcemia occurred in 6.9% (2/29, both with chronic kidney disease stage 3b) of Dmab patients, while none in the ZA group. Conclusion: A single 60-mg dose of denosumab effectively reduces serum calcium levels in PHPT patients with moderate/severe hypercalcemia, at least maintaining efficacy for a median of nearly 3 weeks without serious adverse events.